ARCA Biopharma, Inc. (ABIO) - הון עצמי של החברה

The price action of ARCA Biopharma (ABIO) on the GURU.Markets platform is currently at 0.03. Current indicators are driven by the fact that the company is independently testing new cardiovascular drugs, rejecting mergers in favor of science. The business relies on creating personalized therapy regimens for arrhythmias, while expansion is based on seeking B2B alliances to capture the high-precision pharmaceuticals niche.

ARCA Biopharma focuses on developing high-tech treatments for atrial fibrillation, which requires significant capital expenditures for clinical trials. The company's current balance sheet equity, representing the difference between total assets and all liabilities, demonstrates the real value of the business excluding borrowed funds, allowing investors to assess the issuer's intrinsic stability and the risk of overpaying for shares.